Company News: Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies
– Invention provides unique technology base for therapeutic human bispecific antibodies
– Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes
Merus B.V., a biopharmaceutical company focusing on innovative antibody therapeutics, today announced that it has been granted a European patent on its MeMo® transgenic mouse for the generation of common light chain human antibodies. Using standard industry processes, MeMo®-derived common light chain antibodies can be manufactured in clonal cell lines to efficiently obtain full-length IgG human bispecific antibodies (branded as Biclonics™) for therapy.
“We are very pleased about this important patent as it underlines our unique approach to creating improved antibody therapeutics,” said Ton Logtenberg, CEO of Merus. “MeMo® is distinct from other transgenic mice for human antibodies because the common light chain facilitates co-expression of two antibodies in a single cell to generate functional bispecific antibodies. By screening thousands of bispecific antibodies in cell-based assays, antibody therapeutics with truly superior functional activities are efficiently identified. The full-length IgG format provides for using established, ‘off-the-shelve’ analytical and manufacturing processes which are already in place for therapeutic monoclonal antibodies.”
“This is a major accomplishment of Merus,” said Jason Avery, CBO of Merus. “The company has built an exceptional product and technology base for superior therapeutics that combine the benefits of full-length IgG monoclonal antibodies with the ability of simultaneously addressing multiple disease targets. MeMo® is a source of large panels of high quality human antibodies that may be used to rapidly identify bispecific antibody leads. We are offering biopharmaceutical companies worldwide a non-exclusive license to MeMo®. There are no target restrictions and license terms are flexible.”